CYXO Share Price Performance
SEK 0.018
-0.02 (-57.14%)
Price SEK 0.018
Share PriceSEK 0.018
Cyxone AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
CYXO Community Narratives
There are no narratives available yet.
Recent CYXO News & Updates
Cyxone AB (publ) Key Details
Last Reported Earnings
Jun 30, 2024
Next Reporting Earnings
Feb 25, 2025
- Earnings per share (EPS)
- -0.059
- Gross Margin
- 100.00%
- Net Profit Margin
- -629.96%
- Debt/Equity Ratio
- 0%
Cyxone AB (publ) Competitors
Snowflake Analysis
About CYXO
- Founded
- 2015
- Employees
- 3
- CEO
- WebsiteView website
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Swedish Market Performance
- 7 Days: 1.9%
- 3 Months: 1.2%
- 1 Year: -0.5%
- Year to Date: 3.3%
Over the last 7 days, the market has risen 1.9%, driven by gains of 3.2% in the Industrials sector. As for last year, the market performance has been flat. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›